{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T18:22:57Z","timestamp":1793902977408,"version":"4.8.0"},"reference-count":258,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010663","name":"European Research Council","doi-asserted-by":"publisher","award":["ERC-2021-CoG 101043749"],"award-info":[{"award-number":["ERC-2021-CoG 101043749"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"French National Research Agency","doi-asserted-by":"publisher","award":["ANR-20-CE15-0026"],"award-info":[{"award-number":["ANR-20-CE15-0026"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"French National Research Agency","doi-asserted-by":"publisher","award":["ANR-24-CE18-6970"],"award-info":[{"award-number":["ANR-24-CE18-6970"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004097","name":"ARC Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004097","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.pharmthera.2025.108892","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T20:41:48Z","timestamp":1748637708000},"page":"108892","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Current and future therapeutics targeting mast cells in disease"],"prefix":"10.1016","volume":"273","author":[{"given":"William P.M.","family":"Worrall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent L.","family":"Reber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2025.108892_bb0005","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/nri2782","article-title":"Mast cell-orchestrated immunity to pathogens","volume":"10","author":"Abraham","year":"2010","journal-title":"Nature Reviews. Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0010","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1158\/1078-0432.CCR-17-3795","article-title":"Preclinical antitumor activity of a novel anti-c-KIT antibody-drug conjugate against mutant and wild-type c-KIT-positive solid tumors","volume":"24","author":"Abrams","year":"2018","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0015","series-title":"Novartis Data Show Potential of Remibrutinib as Oral Treatment for Chronic Spontaneous Urticaria, Providing Significant Symptom Improvement by Early Week","volume":"2","author":"AG","year":"2023"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0020","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejphar.2005.12.044","article-title":"Histamine receptors are hot in immunopharmacology","volume":"533","author":"Akdis","year":"2006","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb01245","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.iac.2015.01.010","article-title":"Mast Cell Activation Syndromes Presenting as Anaphylaxis","volume":"35","author":"Akin","year":"2015","journal-title":"Immunology and Allergy Clinics of North America"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0025","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1016\/j.jaci.2022.04.020","article-title":"Tyrosine kinase inhibitors for the treatment of indolent systemic mastocytosis: Are we there yet?","volume":"149","author":"Akin","year":"2022","journal-title":"The Journal of Allergy and Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0030","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S0301-472X(03)00112-7","article-title":"Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit","volume":"31","author":"Akin","year":"2003","journal-title":"Experimental Hematology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0035","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1080\/14712598.2021.1962282","article-title":"The role of omalizumab in the treatment of chronic rhinosinusitis with nasal polyposis","volume":"21","author":"Aldinger","year":"2021","journal-title":"Expert Opinion on Biological Therapy"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0040","series-title":"Allakos Announces Topline Results from its Phase 1 Trial of AK006 in Patients with Chronic Spontaneous Urticaria and Announces Restructuring","author":"Allakos","year":"2025"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0014794","article-title":"IgE mediated autoallergy against thyroid peroxidase--a novel pathomechanism of chronic spontaneous urticaria?","volume":"6","author":"Altrichter","year":"2011","journal-title":"PLoS One"},{"issue":"1683\u20131690","key":"10.1016\/j.pharmthera.2025.108892_bb0050","article-title":"An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria","volume":"149","author":"Altrichter","year":"2022","journal-title":"The Journal of Allergy and Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0055","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1111\/all.15262","article-title":"Anti-KIT monoclonal antibody CDX-0159 induces profound and durable mast cell suppression in a healthy volunteer study","volume":"77","author":"Alvarado","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0060","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jaci.2022.03.021","article-title":"Lirentelimab for severe and chronic forms of allergic conjunctivitis","volume":"150","author":"Anesi","year":"2022","journal-title":"The Journal of Allergy and Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2022.101117","article-title":"Discovery, classification, evolution and diversity of Siglecs","volume":"90","author":"Angata","year":"2023","journal-title":"Molecular Aspects of Medicine"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0070","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1158\/0008-5472.CAN-18-3139","article-title":"ATP-competitive inhibitors midostaurin and avapritinib have distinct resistance profiles in exon 17-mutant KIT","volume":"79","author":"Apsel Winger","year":"2019","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0075","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/cea.12400","article-title":"Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects","volume":"44","author":"Arm","year":"2014","journal-title":"Clinical and Experimental Allergy"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0080","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.pharmthera.2018.05.015","article-title":"Approaches to target IgE antibodies in allergic diseases","volume":"191","author":"Balbino","year":"2018","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0085","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41577-018-0006-6","article-title":"Targeting cytokines to treat asthma and chronic obstructive pulmonary disease","volume":"18","author":"Barnes","year":"2018","journal-title":"Nature Reviews. Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0090","doi-asserted-by":"crossref","DOI":"10.1002\/ski2.195","article-title":"Elevated, FcepsilonRI-dependent MRGPRX2 expression on basophils in chronic urticaria","volume":"3","author":"Bartko","year":"2023","journal-title":"Skin Health Dis"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0095","doi-asserted-by":"crossref","first-page":"1033794","DOI":"10.3389\/fimmu.2022.1033794","article-title":"Inhibition of MRGPRX2 but not FcepsilonRI or MrgprB2-mediated mast cell degranulation by a small molecule inverse receptor agonist","volume":"13","author":"Bawazir","year":"2022","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0100","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejphar.2015.05.070","article-title":"The high-affinity immunoglobulin E receptor as pharmacological target","volume":"778","author":"Blank","year":"2016","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0105","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.coi.2021.03.015","article-title":"The high affinity IgE receptor: A signaling update","volume":"72","author":"Blank","year":"2021","journal-title":"Current Opinion in Immunology"},{"issue":"Suppl. 86","key":"10.1016\/j.pharmthera.2025.108892_bb0110","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1398-9995.2007.01620.x","article-title":"Allergic rhinitis and its impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)","volume":"63","author":"Bousquet","year":"2008","journal-title":"Allergy"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0115","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1398-9995.2007.01569.x","article-title":"Anaphylaxis in patients with mastocytosis: A study on history, clinical features and risk factors in 120 patients","volume":"63","author":"Brockow","year":"2008","journal-title":"Allergy"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0120","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1056\/NEJM200102013440507","article-title":"Asthma","volume":"344","author":"Busse","year":"2001","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0125","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1056\/NEJMoa1613125","article-title":"KIT inhibition by imatinib in patients with severe refractory asthma","volume":"376","author":"Cahill","year":"2017","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0130","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41586-021-04126-6","article-title":"Structure, function and pharmacology of human itch GPCRs","volume":"600","author":"Cao","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0135","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.tips.2023.02.002","article-title":"The structure, function, and pharmacology of MRGPRs","volume":"44","author":"Cao","year":"2023","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0140","doi-asserted-by":"crossref","first-page":"1283370","DOI":"10.3389\/fimmu.2023.1283370","article-title":"Interactions between Siglec-8 and endogenous sialylated cis ligands restrain cell death induction in human eosinophils and mast cells","volume":"14","author":"Cao","year":"2023","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0145","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jaip.2019.02.002","article-title":"Mast cell activation syndrome and Mastocytosis: Initial treatment options and Long-term management","volume":"7","author":"Castells","year":"2019","journal-title":"The Journal of Allergy and Clinical Immunology. In Practice"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0150","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jaci.2024.05.025","article-title":"Mast cell activation syndrome: Current understanding and research needs","volume":"154","author":"Castells","year":"2024","journal-title":"The Journal of Allergy and Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0155","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jaci.2013.12.1090","article-title":"Mastocytosis associated with a rare germline KIT K509I mutation displays a well-differentiated mast cell phenotype","volume":"134","author":"Chan","year":"2014","journal-title":"The Journal of Allergy and Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0160","first-page":"131","article-title":"Briquilimab, an anti-Cd117 antibody, prevents passive systemic anaphylaxis in mice expressing chimeric human\/mouse Cd117","author":"Chang","year":"2023","journal-title":"Annals of Allergy, Asthma & Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0165","first-page":"122","article-title":"Monoclonal antibodies specific for human IgE-producing B cells: A potential therapeutic for IgE-mediated allergic diseases","volume":"8","author":"Chang","year":"1990","journal-title":"Biotechnology (N Y)"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0170","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1111\/all.15843","article-title":"Autoreactive IgE: Pathogenic role and therapeutic target in autoimmune diseases","volume":"78","author":"Charles","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0175","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.cellimm.2018.08.005","article-title":"Mivacurium induce mast cell activation and pseudo-allergic reactions via MAS-related G protein coupled receptor-X2","volume":"332","author":"Che","year":"2018","journal-title":"Cellular Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0180","doi-asserted-by":"crossref","first-page":"17408","DOI":"10.1021\/acs.joc.4c02056","article-title":"Inhibition of kornblum reaction with lithium salts in S(N)2 reactions of sulfonates and a nucleophile containing a pyridine N-oxide moiety: Convergent and selective synthesis of an MRGPRX2 antagonist","volume":"89","author":"Chen","year":"2024","journal-title":"The Journal of Organic Chemistry"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0185","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/s41586-024-08229-8","article-title":"Molecular mechanism of IgE-mediated FcepsilonRI activation","volume":"637","author":"Chen","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0190","doi-asserted-by":"crossref","first-page":"2299597","DOI":"10.1080\/09546634.2023.2299597","article-title":"A systematic review and meta-analysis of efficacy and safety of compound glycyrrhizin combined with second-generation non-sedated antihistamine for the treatment of chronic urticaria","volume":"35","author":"Chen","year":"2024","journal-title":"The Journal of Dermatological Treatment"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0195","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20215247","article-title":"Identification of gain and loss of function missense variants in MRGPRX2\u2019s transmembrane and intracellular domains for mast cell activation by substance P","volume":"20","author":"Chompunud Na Ayudhya","year":"2019","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0200","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12078-019-09277-5","article-title":"The c-kit receptor tyrosine kinase marks sweet or umami sensing T1R3 positive adult taste cells in mice","volume":"14","author":"Choo","year":"2020","journal-title":"Chemosensory Perception"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0205","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1398-9995.2009.02325.x","article-title":"Risk of first-generation H(1)-antihistamines: A GA(2)LEN position paper","volume":"65","author":"Church","year":"2010","journal-title":"Allergy"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0210","series-title":"Incyte provides update on early-phase MRGPRX2 and MRGPRX4 programs","author":"Corporation","year":"2023"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0215","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1111\/all.13587","article-title":"Elevated IgE to tissue factor and thyroglobulin are abated by omalizumab in chronic spontaneous urticaria","volume":"73","author":"Cugno","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.pharmthera.2025.108892_bb01241","doi-asserted-by":"crossref","first-page":"541","DOI":"10.5114\/ada.2018.77605","article-title":"Cutaneous mastocytosis treatment: strategies, limitations and perspectives","volume":"6","author":"Czarny","year":"2018","journal-title":"Advances in Dermatology and Allergology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0220","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2147\/JAA.S337284","article-title":"Efficacy and safety of masitinib in corticosteroid-dependent severe asthma: A randomized placebo-controlled trial","volume":"15","author":"Davidescu","year":"2022","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0225","doi-asserted-by":"crossref","first-page":"9975","DOI":"10.1074\/jbc.M117.776476","article-title":"Allosteric mechanism of action of the therapeutic anti-IgE antibody omalizumab","volume":"292","author":"Davies","year":"2017","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2025.108892_bb01250","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/leu.2017.234","article-title":"Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial","volume":"32","author":"DeAngelo","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0230","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/s41591-021-01538-9","article-title":"Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial","volume":"27","author":"DeAngelo","year":"2021","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0235","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1056\/NEJMoa2012047","article-title":"Anti-Siglec-8 antibody for eosinophilic gastritis and duodenitis","volume":"383","author":"Dellon","year":"2020","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0240","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/s41586-024-07864-5","article-title":"Structural insights into the high-affinity IgE receptor FcepsilonRI complex","volume":"633","author":"Deng","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0245","doi-asserted-by":"crossref","first-page":"1213320","DOI":"10.3389\/fmed.2023.1213320","article-title":"Mast cell-mediated immune regulation in health and disease","volume":"10","author":"Dileepan","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0250","doi-asserted-by":"crossref","first-page":"4759","DOI":"10.1172\/JCI138448","article-title":"Bruton\u2019s tyrosine kinase inhibition effectively protects against human IgE-mediated anaphylaxis","volume":"130","author":"Dispenza","year":"2020","journal-title":"The Journal of Clinical Investigation"},{"issue":"1914\u20131916","key":"10.1016\/j.pharmthera.2025.108892_bb0255","article-title":"Short-term ibrutinib therapy suppresses skin test responses and eliminates IgE-mediated basophil activation in adults with peanut or tree nut allergy","volume":"141","author":"Dispenza","year":"2018","journal-title":"The Journal of Allergy and Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0260","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/0092-8674(93)90540-7","article-title":"Abolition of anaphylaxis by targeted disruption of the high affinity immunoglobulin E receptor alpha chain gene","volume":"75","author":"Dombrowicz","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007258","article-title":"Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT","volume":"4","author":"Dubreuil","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0270","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.immuni.2011.03.028","article-title":"Mast cells are key promoters of contact allergy that mediate the adjuvant effects of haptens","volume":"34","author":"Dudeck","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0275","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/ni.3445","article-title":"Expression profiling of constitutive mast cells reveals a unique identity within the immune system","volume":"17","author":"Dwyer","year":"2016","journal-title":"Nature Immunology"},{"issue":"1709\u20131719","key":"10.1016\/j.pharmthera.2025.108892_bb0280","article-title":"Accelerated dissociation of IgE-FcepsilonRI complexes by disruptive inhibitors actively desensitizes allergic effector cells","volume":"133","author":"Eggel","year":"2014","journal-title":"The Journal of Allergy and Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0285","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/imr.13380","article-title":"Therapeutic monoclonal antibodies in allergy: Targeting IgE, cytokine, and alarmin pathways","volume":"328","author":"Eggel","year":"2024","journal-title":"Immunological Reviews"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0290","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.alit.2023.05.003","article-title":"Chronic urticaria and the pathogenic role of mast cells","volume":"72","author":"Elieh-Ali-Komi","year":"2023","journal-title":"Allergology International"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0295","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao1690","article-title":"A precision therapy against cancers driven by KIT\/PDGFRA mutations","volume":"9","author":"Evans","year":"2017","journal-title":"Science Translational Medicine"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0300","series-title":"EVO756-HV001: Oral presentation. In","author":"Evommune","year":"2024"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0305","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.immuni.2011.09.015","article-title":"Cre-mediated cell ablation contests mast cell contribution in models of antibody- and T cell-mediated autoimmunity","volume":"35","author":"Feyerabend","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0310","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.coi.2010.10.005","article-title":"Peanut allergy and anaphylaxis","volume":"22","author":"Finkelman","year":"2010","journal-title":"Current Opinion in Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0315","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0091-6749(99)70091-6","article-title":"A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria","volume":"104","author":"Finn","year":"1999","journal-title":"The Journal of Allergy and Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0320","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/all.14037","article-title":"Prevalence of chronic urticaria in children and adults across the globe: Systematic review with meta-analysis","volume":"75","author":"Fricke","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0325","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1146\/annurev.immunol.21.120601.141025","article-title":"Mast cells as \u201ctunable\u201d effector and immunoregulatory cells: Recent advances","volume":"23","author":"Galli","year":"2005","journal-title":"Annual Review of Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0330","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s40629-020-00118-6","article-title":"Mast cells and IgE in defense against lethality of venoms: Possible \u201cbenefit\u201d of allergy","volume":"29","author":"Galli","year":"2020","journal-title":"Allergo Journal International"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0335","first-page":"193","article-title":"Mast cells and IgE can enhance survival during innate and acquired host responses to venoms","volume":"128","author":"Galli","year":"2017","journal-title":"Transactions of the American Clinical and Climatological Association"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0340","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1182\/blood-2023-185533","volume":"142","author":"Gandhi","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0345","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/35018500","article-title":"Structure of the fc fragment of human IgE bound to its high-affinity receptor Fc epsilonRI alpha","volume":"406","author":"Garman","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0350","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41467-019-13815-w","article-title":"The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab","volume":"11","author":"Gasser","year":"2020","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0355","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1172\/JCI85538","article-title":"Different activation signals induce distinct mast cell degranulation strategies","volume":"126","author":"Gaudenzio","year":"2016","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0360","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/315577a0","article-title":"Inhibition of the Prausnitz-Kustner reaction by an immunoglobulin epsilon-chain fragment synthesized in E. Coli","volume":"315","author":"Geha","year":"1985","journal-title":"Nature"},{"issue":"1160\u20131171","key":"10.1016\/j.pharmthera.2025.108892_bb0365","article-title":"Hemogenic endothelial fate mapping reveals dual developmental origin of mast cells","volume":"48","author":"Gentek","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0370","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1182\/blood-2005-04-1568","article-title":"Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation","volume":"106","author":"Gotlib","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0375","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200339","article-title":"Avapritinib versus placebo in indolent systemic mastocytosis","volume":"2","author":"Gotlib","year":"2023","journal-title":"NEJM Evidence"},{"key":"10.1016\/j.pharmthera.2025.108892_bb01244","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"New England journal of medicine"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0380","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1038\/s41591-021-01539-8","article-title":"Efficacy and safety of avapritinib in advanced systemic mastocytosis: Interim analysis of the phase 2 PATHFINDER trial","volume":"27","author":"Gotlib","year":"2021","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0385","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nri2273","article-title":"IgE in allergy and asthma today","volume":"8","author":"Gould","year":"2008","journal-title":"Nature Reviews. Immunology"},{"issue":"412\u2013420","key":"10.1016\/j.pharmthera.2025.108892_bb0390","article-title":"A mast-cell-specific receptor mediates neurogenic inflammation and pain","volume":"101","author":"Green","year":"2019","journal-title":"Neuron"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0395","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1172\/JCI68964","article-title":"Serum IgE clearance is facilitated by human FcepsilonRI internalization","volume":"124","author":"Greer","year":"2014","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0400","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/1523-1747.ep12338471","article-title":"KIT expression reveals a population of precursor melanocytes in human skin","volume":"106","author":"Grichnik","year":"1996","journal-title":"The Journal of Investigative Dermatology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb01246","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1182\/blood-2004-12-4617","article-title":"Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412","volume":"106","author":"Growney","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108167","article-title":"Pharmacological approaches to target type 2 cytokines in asthma","volume":"237","author":"Guilleminault","year":"2022","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0410","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/bjd.14768","article-title":"Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: A systematic review and meta-analysis","volume":"175","author":"Guillen-Aguinaga","year":"2016","journal-title":"The British Journal of Dermatology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0415","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.iac.2021.09.007","article-title":"Anaphylaxis and mast cell disorders","volume":"42","author":"Gulen","year":"2022","journal-title":"Immunology and Allergy Clinics of North America"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0420","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1111\/all.14308","article-title":"Past, present, and future of anti-IgE biologics","volume":"75","author":"Guntern","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0425","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1111\/j.1939-1676.2008.0190.x","article-title":"Masitinib is safe and effective for the treatment of canine mast cell tumors","volume":"22","author":"Hahn","year":"2008","journal-title":"Journal of Veterinary Internal Medicine"},{"issue":"Suppl. 2","key":"10.1016\/j.pharmthera.2025.108892_bb0430","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000350388","article-title":"Significantly high levels of anti-dsDNA immunoglobulin E in sera and the ability of dsDNA to induce the degranulation of basophils from chronic urticaria patients","volume":"161","author":"Hatada","year":"2013","journal-title":"International Archives of Allergy and Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb01248","first-page":"4342","article-title":"Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor","volume":"21","author":"Heinrich","year":"2003","journal-title":"Journal of Oncology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0435","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.V96.3.925","article-title":"Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor","volume":"96","author":"Heinrich","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0440","first-page":"769","article-title":"Coexpression of the c-kit and stem cell factor genes in breast carcinomas","volume":"6","author":"Hines","year":"1995","journal-title":"Cell Growth & Differentiation"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0445","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.3389\/fimmu.2018.01392","article-title":"Molecular regulation of histamine synthesis","volume":"9","author":"Huang","year":"2018","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0450","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/j.1398-9995.2009.02122.x","article-title":"Masitinib, a c-kit\/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics","volume":"64","author":"Humbert","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0455","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1182\/blood-2004-02-0631","article-title":"Kit and FcepsilonRI mediate unique and convergent signals for release of inflammatory mediators from human mast cells","volume":"104","author":"Hundley","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0460","series-title":"Allakos announces phase 2 lirentelimab trials in atopic dermatitis. In","author":"Inc.","year":"2023"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0465","series-title":"Allakos announces positive results from its ongoing phase 1 trial of AK006 in healthy volunteers, with AK006 demonstrating high receptor occupancy on mast cells and a favorable safety profile. In","author":"Inc.","year":"2024"},{"issue":"479\u2013486","key":"10.1016\/j.pharmthera.2025.108892_bb0470","article-title":"Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks","volume":"153","author":"Jain","year":"2024","journal-title":"The Journal of Allergy and Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0475","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1182\/blood.2020009192","article-title":"Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia","volume":"138","author":"Jetani","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0480","doi-asserted-by":"crossref","first-page":"S390","DOI":"10.1016\/j.jaci.2004.12.014","article-title":"Clinical outcomes and adverse effect monitoring in allergic rhinitis","volume":"115","author":"Juniper","year":"2005","journal-title":"The Journal of Allergy and Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0485","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/0091-6749(81)90134-2","article-title":"Effects of infused histamine: Analysis of the effects of H-1 and H-2 histamine receptor antagonists on cardiovascular and pulmonary responses","volume":"68","author":"Kaliner","year":"1981","journal-title":"The Journal of Allergy and Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0490","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1634\/theoncologist.2018-0222","article-title":"FDA approval summary: Midostaurin for the treatment of advanced systemic mastocytosis","volume":"23","author":"Kasamon","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0495","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/0091-6749(85)90638-4","article-title":"Heterogeneity of mammalian mast cells differentiated in vivo and in vitro","volume":"76","author":"Katz","year":"1985","journal-title":"The Journal of Allergy and Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0500","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.4049\/jimmunol.161.4.1795","article-title":"Multiple signaling pathways for the activation of JNK in mast cells: Involvement of Bruton\u2019s tyrosine kinase, protein kinase C, and JNK kinases, SEK1 and MKK7","volume":"161","author":"Kawakami","year":"1998","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0505","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.4049\/jimmunol.165.3.1210","article-title":"Redundant and opposing functions of two tyrosine kinases, Btk and Lyn, in mast cell activation","volume":"165","author":"Kawakami","year":"2000","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0510","first-page":"5108","article-title":"Tyrosine phosphorylation and activation of Bruton tyrosine kinase upon Fc epsilon RI cross-linking","volume":"14","author":"Kawakami","year":"1994","journal-title":"Molecular and Cellular Biology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0515","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jaci.2024.11.009","article-title":"Importance of mast cell histamine secretion in IgG-mediated systemic anaphylaxis","volume":"155","author":"Khodoun","year":"2025","journal-title":"The Journal of Allergy and Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0520","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1067\/mai.2000.107127","article-title":"Identification of SAF-2, a novel siglec expressed on eosinophils, mast cells, and basophils","volume":"105","author":"Kikly","year":"2000","journal-title":"The Journal of Allergy and Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0525","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.pharmthera.2012.06.005","article-title":"Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions","volume":"135","author":"Kiwamoto","year":"2012","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0530","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jaci.2022.09.004","article-title":"MRGPRX2 in drug allergy: What we know and what we do not know","volume":"151","author":"Kolkhir","year":"2023","journal-title":"The Journal of Allergy and Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0535","first-page":"620","article-title":"Mast cell: A multi-functional master cell","volume":"6","author":"Krystel-Whittemore","year":"2015","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0540","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jaci.2020.08.027","article-title":"Mas-related G protein-coupled receptor X2 and its activators in dermatologic allergies","volume":"147","author":"Kuhn","year":"2021","journal-title":"The Journal of Allergy and Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0545","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jaci.2022.12.805","article-title":"Novel small molecule MRGPRX2 antagonists inhibit a murine model of allergic reaction","volume":"151","author":"Kumar","year":"2023","journal-title":"The Journal of Allergy and Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0550","doi-asserted-by":"crossref","DOI":"10.3390\/cells10051033","article-title":"Unlocking the non-IgE-mediated pseudo-allergic reaction puzzle with mas-related G-protein coupled receptor member X2 (MRGPRX2)","volume":"10","author":"Kumar","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0555","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1182\/blood-2018-06-853879","article-title":"Anti-human CD117 antibody-mediated bone marrow niche clearance in nonhuman primates and humanized NSG mice","volume":"133","author":"Kwon","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0560","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nchembio.2334","article-title":"In silico design of novel probes for the atypical opioid receptor MRGPRX2","volume":"13","author":"Lansu","year":"2017","journal-title":"Nature Chemical Biology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0565","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/j.semdp.2006.08.006","article-title":"KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs)","volume":"23","author":"Lasota","year":"2006","journal-title":"Seminars in Diagnostic Pathology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0570","first-page":"133","article-title":"Briquilimab is well-tolerated and effectively depletes tissue resident mast cells in non-human primates","author":"Lee","year":"2024","journal-title":"Annals of Allergy, Asthma & Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0575","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00428-022-03423-3","article-title":"The international consensus classification of mastocytosis and related entities","volume":"482","author":"Leguit","year":"2023","journal-title":"Virchows Archiv"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0580","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1046\/j.0954-7894.2002.01314.x","article-title":"H1-antihistamines: Inverse agonism, anti-inflammatory actions and cardiac effects","volume":"32","author":"Leurs","year":"2002","journal-title":"Clinical and Experimental Allergy"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0585","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/cea.12045","article-title":"Heterogeneity in the responses of human lung mast cells to stem cell factor","volume":"43","author":"Lewis","year":"2013","journal-title":"Clinical and Experimental Allergy"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0590","first-page":"15","article-title":"Review and updates on systemic mastocytosis and related entities","author":"Li","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"640\u2013653","key":"10.1016\/j.pharmthera.2025.108892_bb0595","article-title":"Adult connective tissue-resident mast cells originate from late erythro-myeloid progenitors","volume":"49","author":"Li","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0600","doi-asserted-by":"crossref","first-page":"6930","DOI":"10.1182\/blood-2011-03-343962","article-title":"Reduced mast cell and basophil numbers and function in Cpa3-Cre; Mcl-1fl\/fl mice","volume":"118","author":"Lilla","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0605","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: Survival studies and prognostic factors","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0610","author":"Lindsay","year":"2024"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0615","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1158\/1078-0432.CCR-17-3786","article-title":"Mechanistic insights of an immunological adverse event induced by an anti-KIT antibody drug conjugate and mitigation strategies","volume":"24","author":"L\u2019Italien","year":"2018","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0620","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1158\/1078-0432.CCR-16-2152","article-title":"KTN0158, a humanized anti-KIT monoclonal antibody, demonstrates biologic activity against both normal and malignant canine mast cells","volume":"23","author":"London","year":"2017","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0625","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S0140-6736(16)31403-9","article-title":"Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: A randomised, placebo-controlled, phase 3 study","volume":"389","author":"Lortholary","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0630","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/s41375-019-0450-8","article-title":"Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis","volume":"33","author":"Lubke","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0635","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nri3737","article-title":"Siglec-mediated regulation of immune cell function in disease","volume":"14","author":"Macauley","year":"2014","journal-title":"Nature Reviews. Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0640","doi-asserted-by":"crossref","first-page":"1433982","DOI":"10.3389\/fimmu.2024.1433982","article-title":"Pharmacological blockade of the mast cell MRGPRX2 receptor supports investigation of its relevance in skin disorders","volume":"15","author":"Macphee","year":"2024","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb01247","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s10147-007-0699-1","article-title":"The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias","volume":"12","author":"Maekawa","year":"2007","journal-title":"International Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0645","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1067\/mai.2002.125977","article-title":"The control effect of histamine on body temperature and respiratory function in IgE-dependent systemic anaphylaxis","volume":"110","author":"Makabe-Kobayashi","year":"2002","journal-title":"The Journal of Allergy and Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0650","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0385-8146(89)80039-2","article-title":"Follow-up study of reconstructed auricle in microtia: Comparison of the results of the rib cartilage framework and the silicone rubber framework methods","volume":"16","author":"Matsunaga","year":"1989","journal-title":"Auris Nasus Larynx"},{"issue":"417\u2013431","key":"10.1016\/j.pharmthera.2025.108892_bb0655","article-title":"An allosteric anti-tryptase antibody for the treatment of mast cell-mediated severe Asthma","volume":"179","author":"Maun","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0660","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0140-6736(23)01684-7","article-title":"Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: Results of two phase 3 randomised controlled trials","volume":"403","author":"Maurer","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2023.11.873","article-title":"Barzolvolimab significantly decreases chronic spontaneous urticaria disease activity and is well tolerated: Top line results from a phase 2 trial","volume":"153","author":"Maurer","year":"2024","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0670","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.jaci.2017.06.032","article-title":"Omalizumab treatment in patients with chronic inducible urticaria: A systematic review of published evidence","volume":"141","author":"Maurer","year":"2018","journal-title":"The Journal of Allergy and Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0675","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/cea.13309","article-title":"Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study","volume":"49","author":"Maurer","year":"2019","journal-title":"Clinical and Experimental Allergy"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0680","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0685","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/cea.12900","article-title":"H1-antihistamine-refractory chronic spontaneous urticaria: It\u2019s worse than we thought - first results of the multicenter real-life AWARE study","volume":"47","author":"Maurer","year":"2017","journal-title":"Clinical and Experimental Allergy"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0690","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/imm.13416","article-title":"The role of Bruton's tyrosine kinase in the immune system and disease","volume":"164","author":"McDonald","year":"2021","journal-title":"Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0695","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/87603","article-title":"The structure of the IgE Cepsilon2 domain and its role in stabilizing the complex with its high-affinity receptor FcepsilonRIalpha","volume":"8","author":"McDonnell","year":"2001","journal-title":"Nature Structural Biology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0700","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-immunol-061020-053712","article-title":"IgE, IgE receptors and anti-IgE biologics: Protein structures and mechanisms of action","volume":"41","author":"McDonnell","year":"2023","journal-title":"Annual Review of Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0705","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1165\/rcmb.2016-0356OC","article-title":"House dust mite-induced allergic airway disease is independent of IgE and FcepsilonRIalpha","volume":"57","author":"McKnight","year":"2017","journal-title":"American Journal of Respiratory Cell and Molecular Biology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0710","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.676354","article-title":"MRGPRX2 and adverse drug reactions","volume":"12","author":"McNeil","year":"2021","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0715","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature14022","article-title":"Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions","volume":"519","author":"McNeil","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0720","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1111\/all.15261","article-title":"Bruton's tyrosine kinase inhibition-An emerging therapeutic strategy in immune-mediated dermatological conditions","volume":"77","author":"Mendes-Bastos","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0725","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/all.15850","article-title":"Mast cell silencing: A novel therapeutic approach for urticaria and other mast cell-mediated diseases","volume":"79","author":"Metz","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0730","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/112_2020_53","article-title":"Ligands and signaling of mas-related G protein-coupled receptor-X2 in mast cell activation","volume":"179","author":"Mi","year":"2021","journal-title":"Reviews of Physiology, Biochemistry and Pharmacology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0735","first-page":"1163","article-title":"Hepatic involvement in mastocytosis: Clinicopathologic correlations in 41 cases","volume":"22","author":"Mican","year":"1995","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0740","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/0952-7915(89)90033-2","article-title":"Human mast cell proteases and mast cell heterogeneity","volume":"1","author":"Miller","year":"1989","journal-title":"Current Opinion in Immunology"},{"issue":"711\u2013724","key":"10.1016\/j.pharmthera.2025.108892_bb0745","article-title":"Siglec-9 is an inhibitory receptor on human mast cells in vitro","volume":"152","author":"Miralda","year":"2023","journal-title":"The Journal of Allergy and Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0750","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.alit.2019.12.003","article-title":"IL-24: A new player in the pathogenesis of pro-inflammatory and allergic skin diseases","volume":"69","author":"Mitamura","year":"2020","journal-title":"Allergology International"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0755","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jaci.2014.03.031","article-title":"Siglec-7 is an inhibitory receptor on human mast cells and basophils","volume":"134","author":"Mizrahi","year":"2014","journal-title":"The Journal of Allergy and Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0760","doi-asserted-by":"crossref","first-page":"66299","DOI":"10.18632\/oncotarget.11812","article-title":"Mast cell sarcoma: New cases and literature review","volume":"7","author":"Monnier","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0765","first-page":"939","article-title":"Proto-oncogene c-kit expression in malignant melanoma: Protein loss with tumor progression","volume":"10","author":"Montone","year":"1997","journal-title":"Modern Pathology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0770","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00281-016-0565-1","article-title":"IgE and mast cells in host defense against parasites and venoms","volume":"38","author":"Mukai","year":"2016","journal-title":"Seminars in Immunopathology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0775","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/all.15032","article-title":"EAACI guidelines: Anaphylaxis (2021 update)","volume":"77","author":"Muraro","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0780","doi-asserted-by":"crossref","DOI":"10.3390\/cells11040622","article-title":"FcepsilonRI: A master regulator of mast cell functions","volume":"11","author":"Nagata","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0785","article-title":"A highly selective KIT inhibitor MOD000001 suppresses IgE-mediated mast cell activation","volume":"3","author":"Nakamura","year":"2024","journal-title":"J Allergy Clin Immunol Glob"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0790","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/eji.201343838","article-title":"Histamine synthesis is required for granule maturation in murine mast cells","volume":"44","author":"Nakazawa","year":"2014","journal-title":"European Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0795","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1365-2133.2005.07049.x","article-title":"Levocetirizine in the treatment of chronic idiopathic urticaria: A randomized, double-blind, placebo-controlled study","volume":"154","author":"Nettis","year":"2006","journal-title":"The British Journal of Dermatology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0800","doi-asserted-by":"crossref","first-page":"5014","DOI":"10.1182\/blood-2002-10-3058","article-title":"Ligation of Siglec-8: A selective mechanism for induction of human eosinophil apoptosis","volume":"101","author":"Nutku","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0805","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/JLB.2AB1018-405R","article-title":"Novel MRGPRX2 antagonists inhibit IgE-independent activation of human umbilical cord blood-derived mast cells","volume":"106","author":"Ogasawara","year":"2019","journal-title":"Journal of Leukocyte Biology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0810","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.immuni.2010.08.011","article-title":"Basophils orchestrate chronic allergic dermatitis and protective immunity against helminths","volume":"33","author":"Ohnmacht","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0815","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2165\/00128071-200708010-00005","article-title":"Efficacy and safety of desloratadine in adults with chronic idiopathic urticaria: A randomized, double-blind, placebo-controlled, multicenter trial","volume":"8","author":"Ortonne","year":"2007","journal-title":"American Journal of Clinical Dermatology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0820","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/JLB.2HI0917-391R","article-title":"Frontline science: Characterization of a novel mouse strain expressing human Siglec-8 only on eosinophils","volume":"104","author":"O\u2019Sullivan","year":"2018","journal-title":"Journal of Leukocyte Biology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0825","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2023.101799","article-title":"Siglecs as potential targets of therapy in human mast cell- and\/or eosinophil-associated diseases","volume":"69","author":"O\u2019Sullivan","year":"2023","journal-title":"Seminars in Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0830","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1182\/blood-2018-06-858159","article-title":"Anti-CD117 antibody depletes normal and myelodysplastic syndrome human hematopoietic stem cells in xenografted mice","volume":"133","author":"Pang","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0835","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(03)14115-3","article-title":"Imatinib for systemic mast-cell disease","volume":"362","author":"Pardanani","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0840","doi-asserted-by":"crossref","first-page":"22729","DOI":"10.1074\/jbc.274.32.22729","article-title":"OB-BP1\/Siglec-6. A leptin- and sialic acid-binding protein of the immunoglobulin superfamily","volume":"274","author":"Patel","year":"1999","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0845","doi-asserted-by":"crossref","first-page":"157","DOI":"10.5415\/apallergy.2011.1.3.157","article-title":"Overview on the pathomechanisms of allergic rhinitis","volume":"1","author":"Pawankar","year":"2011","journal-title":"Asia Pacific Allergy"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0850","first-page":"17","article-title":"Don\u2019t want to lose nursing hours on account of new education","volume":"88","author":"Pedersen","year":"1988","journal-title":"Sygeplejersken"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0855","doi-asserted-by":"crossref","first-page":"11610","DOI":"10.1038\/ncomms11610","article-title":"Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange","volume":"7","author":"Pennington","year":"2016","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0860","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/imr.12623","article-title":"The contribution of mast cells to bacterial and fungal infection immunity","volume":"282","author":"Piliponsky","year":"2018","journal-title":"Immunological Reviews"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0865","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1056\/NEJMcp044141","article-title":"Clinical practice. Allergic rhinitis","volume":"353","author":"Plaut","year":"2005","journal-title":"The New England Journal of Medicine"},{"issue":"404\u2013416","key":"10.1016\/j.pharmthera.2025.108892_bb0870","article-title":"Human mast cell proteome reveals unique lineage, putative functions, and structural basis for cell ablation","volume":"52","author":"Plum","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0875","first-page":"44","article-title":"Efficacy and safety of up-dosed second-generation antihistamines in uncontrolled chronic spontaneous urticaria: A review","volume":"16","author":"Podder","year":"2023","journal-title":"The Journal of Clinical and Aesthetic Dermatology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0880","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/bjh.18116","article-title":"KIT D816V is dimerization-independent and activates downstream pathways frequently perturbed in mastocytosis","volume":"202","author":"Rajan","year":"2023","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0885","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ejphar.2005.12.067","article-title":"Stem cell factor and its receptor c-Kit as targets for inflammatory diseases","volume":"533","author":"Reber","year":"2006","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0890","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jaci.2017.06.003","article-title":"The pathophysiology of anaphylaxis","volume":"140","author":"Reber","year":"2017","journal-title":"The Journal of Allergy and Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0895","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.it.2012.09.008","article-title":"New models for analyzing mast cell functions in vivo","volume":"33","author":"Reber","year":"2012","journal-title":"Trends in Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0900","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/mi.2014.131","article-title":"Potential effector and immunoregulatory functions of mast cells in mucosal immunity","volume":"8","author":"Reber","year":"2015","journal-title":"Mucosal Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0905","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1038\/s41375-022-01615-z","article-title":"Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis","volume":"36","author":"Reiter","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0910","doi-asserted-by":"crossref","first-page":"17832","DOI":"10.1073\/pnas.1317118110","article-title":"Structural basis for KIT receptor tyrosine kinase inhibition by antibodies targeting the D4 membrane-proximal region","volume":"110","author":"Reshetnyak","year":"2013","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0915","doi-asserted-by":"crossref","DOI":"10.3390\/cells11071138","article-title":"Functional and phenotypic characterization of Siglec-6 on human mast cells","volume":"11","author":"Robida","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0920","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/BF03343784","article-title":"Role of c-kit in mammalian spermatogenesis","volume":"23","author":"Rossi","year":"2000","journal-title":"Journal of Endocrinological Investigation"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0925","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/cts.13163","article-title":"Dose-dependent inactivation of airway tryptase with a novel dissociating anti-tryptase antibody (MTPS9579A) in healthy participants: A randomized trial","volume":"15","author":"Rymut","year":"2022","journal-title":"Clinical and Translational Science"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0930","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11882-023-01123-9","article-title":"Mast cell-targeting therapies in mast cell activation syndromes","volume":"24","author":"Sabato","year":"2024","journal-title":"Current Allergy and Asthma Reports"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0935","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.imlet.2020.02.003","article-title":"Identification of antigenic epitopes of thyroperoxidase, thyroglobulin and interleukin-24. Exploration of cross-reactivity with environmental allergens and possible role in urticaria and hypothyroidism","volume":"220","author":"Sanchez","year":"2020","journal-title":"Immunology Letters"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0940","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1038\/s42003-022-04207-w","article-title":"Discovery of an agonistic Siglec-6 antibody that inhibits and reduces human mast cells","volume":"5","author":"Schanin","year":"2022","journal-title":"Communications Biology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0945","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jaci.2017.10.035","article-title":"IL-24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria","volume":"142","author":"Schmetzer","year":"2018","journal-title":"The Journal of Allergy and Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0950","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1038\/s41467-023-38030-6","article-title":"Siglec-6 mediates the uptake of extracellular vesicles through a noncanonical glycolipid binding pocket","volume":"14","author":"Schmidt","year":"2023","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0955","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.iac.2006.05.010","article-title":"Diagnostic value of tryptase in anaphylaxis and mastocytosis","volume":"26","author":"Schwartz","year":"2006","journal-title":"Immunology and Allergy Clinics of North America"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0960","doi-asserted-by":"crossref","first-page":"5667","DOI":"10.4049\/jimmunol.170.11.5667","article-title":"Tryptase precursors are preferentially and spontaneously released, whereas mature tryptase is retained by HMC-1 cells, Mono-Mac-6 cells, and human skin-derived mast cells","volume":"170","author":"Schwartz","year":"2003","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0965","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1038\/s41590-019-0493-z","article-title":"House dust mites activate nociceptor-mast cell clusters to drive type 2 skin inflammation","volume":"20","author":"Serhan","year":"2019","journal-title":"Nature Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0970","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1038\/s41590-019-0493-z","article-title":"House dust mites activate nociceptor\u2013mast cell clusters to drive type 2 skin inflammation","volume":"20","author":"Serhan","year":"2019","journal-title":"Nature Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0975","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2021.135724","article-title":"Mas-related G protein-coupled receptors (Mrgprs) - key regulators of neuroimmune interactions","volume":"749","author":"Serhan","year":"2021","journal-title":"Neuroscience Letters"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0980","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0165-2478(98)00086-8","article-title":"Defective degranulation and calcium mobilization of bone-marrow derived mast cells from Xid and Btk-deficient mice","volume":"64","author":"Setoguchi","year":"1998","journal-title":"Immunology Letters"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0985","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/j.1398-9995.2007.01435.x","article-title":"H1-antihistamines for the treatment of anaphylaxis: Cochrane systematic review","volume":"62","author":"Sheikh","year":"2007","journal-title":"Allergy"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0990","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/HTR.0000000000000081","article-title":"Comparative effectiveness, covariates, complex treatment, and complex outcomes: a response to Dahdah et al. [Corrected]","volume":"29","author":"Sherer","year":"2014","journal-title":"The Journal of Head Trauma Rehabilitation"},{"key":"10.1016\/j.pharmthera.2025.108892_bb0995","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3346\/jkms.2015.30.6.705","article-title":"Serum specific IgE to thyroid peroxidase activates basophils in aspirin intolerant urticaria","volume":"30","author":"Shin","year":"2015","journal-title":"Journal of Korean Medical Science"},{"key":"10.1016\/j.pharmthera.2025.108892_bb1000","doi-asserted-by":"crossref","first-page":"13696","DOI":"10.1038\/ncomms13696","article-title":"A TNFRSF14-FcvarepsilonRI-mast cell pathway contributes to development of multiple features of asthma pathology in mice","volume":"7","author":"Sibilano","year":"2016","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2025.108892_bb1005","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1016\/j.jaci.2009.08.028","article-title":"Food allergy","volume":"125","author":"Sicherer","year":"2010","journal-title":"The Journal of Allergy and Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb1010","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/bjd\/ljad191","article-title":"Safety and efficacy of lirentelimab in patients with refractory indolent systemic mastocytosis: A first-in-human clinical trial","volume":"189","author":"Siebenhaar","year":"2023","journal-title":"The British Journal of Dermatology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb1015","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1067\/mai.2001.113866","article-title":"Prevention of acute urticaria in young children with atopic dermatitis","volume":"107","author":"Simons","year":"2001","journal-title":"The Journal of Allergy and Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb1020","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/S0091-6749(03)01876-1","article-title":"H1-antihistamines: More relevant than ever in the treatment of allergic disorders","volume":"112","author":"Simons","year":"2003","journal-title":"The Journal of Allergy and Clinical Immunology"},{"issue":"1139\u20131150","key":"10.1016\/j.pharmthera.2025.108892_bb1030","article-title":"Histamine and H1-antihistamines: Celebrating a century of progress","volume":"128","author":"Simons","year":"2011","journal-title":"The Journal of Allergy and Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb1025","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S1081-1206(10)60662-X","article-title":"H1-antihistamine treatment in young atopic children: Effect on urticaria","volume":"99","author":"Simons","year":"2007","journal-title":"Annals of Allergy, Asthma & Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb1035","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1111\/all.13166","article-title":"BTK inhibition is a potent approach to block IgE-mediated histamine release in human basophils","volume":"72","author":"Smiljkovic","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.pharmthera.2025.108892_bb1040","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jaci.2022.07.018","article-title":"Expression and regulation of Siglec-6 (CD327) on human mast cells and basophils","volume":"151","author":"Smiljkovic","year":"2023","journal-title":"The Journal of Allergy and Clinical Immunology"},{"issue":"866\u2013873","key":"10.1016\/j.pharmthera.2025.108892_bb1045","first-page":"e861","article-title":"Gastrointestinal manifestations in mastocytosis: A study of 83 patients","volume":"132","author":"Sokol","year":"2013","journal-title":"The Journal of Allergy and Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb1050","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41577-022-00731-2","article-title":"New perspectives on the origins and heterogeneity of mast cells","volume":"23","author":"St John","year":"2023","journal-title":"Nature Reviews. Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb1055","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1182\/bloodadvances.2017011080","article-title":"Midostaurin: Its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis","volume":"2","author":"Stone","year":"2018","journal-title":"Blood Advances"},{"key":"10.1016\/j.pharmthera.2025.108892_bb1060","doi-asserted-by":"crossref","first-page":"44739","DOI":"10.1074\/jbc.M111.277152","article-title":"Mas-related gene X2 (MrgX2) is a novel G protein-coupled receptor for the antimicrobial peptide LL-37 in human mast cells: Resistance to receptor phosphorylation, desensitization, and internalization","volume":"286","author":"Subramanian","year":"2011","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2025.108892_bb1065","doi-asserted-by":"crossref","DOI":"10.1172\/JCI172335","article-title":"A phase II study of Bruton\u2019s tyrosine kinase inhibition for the prevention of anaphylaxis","volume":"133","author":"Suresh","year":"2023","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2025.108892_bb1070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173104","article-title":"A novel MRGPRX2-targeting antagonistic DNA aptamer inhibits histamine release and prevents mast cell-mediated anaphylaxis","volume":"878","author":"Suzuki","year":"2020","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb01249","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-188904","article-title":"Elenestinib, an Investigational, Next Generation KIT D816V Inhibitor, Reduces Mast Cell Burden, Improves Symptoms, and Has a Favorable Safety Profile in Patients with Indolent Systemic Mastocytosis: Analysis of the Harbor Trial","volume":"142","author":"Tashi","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2025.108892_bb1075","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.bbrc.2006.08.177","article-title":"Immunoglobulin E-independent activation of mast cell is mediated by Mrg receptors","volume":"349","author":"Tatemoto","year":"2006","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2025.108892_bb1080","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20230570","article-title":"Landscape of mast cell populations across organs in mice and humans","volume":"220","author":"Tauber","year":"2023","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/j.pharmthera.2025.108892_bb1085","first-page":"427","article-title":"Stem-cell factor, the kit ligand, induces direct degranulation of rat peritoneal mast cells in vitro and in vivo: Dependence of the in vitro effect on period of culture and comparisons of stem-cell factor with other mast cell-activating agents","volume":"86","author":"Taylor","year":"1995","journal-title":"Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb1090","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/all.15585","article-title":"Anti-KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria","volume":"78","author":"Terhorst-Molawi","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.pharmthera.2025.108892_bb1095","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.3389\/fimmu.2018.01873","article-title":"The role of histamine and histamine receptors in mast cell-mediated allergy and inflammation: The hunt for new therapeutic targets","volume":"9","author":"Thangam","year":"2018","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb1100","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4137\/CCRPM.S7793","article-title":"Omalizumab: Clinical use for the management of asthma","volume":"6","author":"Thomson","year":"2012","journal-title":"Clin Med Insights Circ Respir Pulm Med"},{"key":"10.1016\/j.pharmthera.2025.108892_bb1105","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12885-022-10498-3","article-title":"Comprehensive mastocytosis data analysis from a single center","volume":"23","author":"Tiryaki","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pharmthera.2025.108892_bb1110","doi-asserted-by":"crossref","first-page":"1026304","DOI":"10.3389\/fimmu.2022.1026304","article-title":"Mas-related G protein-coupled receptor MRGPRX2 in human basophils: Expression and functional studies","volume":"13","author":"Toscano","year":"2022","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb1115","first-page":"4","article-title":"Pathology of the lymph node and spleen in systemic mast cell disease","volume":"1","author":"Travis","year":"1988","journal-title":"Modern Pathology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb1120","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1255","article-title":"Ligelizumab treatment for severe asthma: Learnings from the clinical development programme","volume":"10","author":"Trischler","year":"2021","journal-title":"Clinical & Translational Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb1125","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.jaci.2022.04.012","article-title":"KIT as a master regulator of the mast cell lineage","volume":"149","author":"Tsai","year":"2022","journal-title":"The Journal of Allergy and Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb1130","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/ACI.0000000000000305","article-title":"Epidemiology of severe anaphylaxis: Can we use population-based data to understand anaphylaxis?","volume":"16","author":"Turner","year":"2016","journal-title":"Current Opinion in Allergy and Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb1135","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000646","article-title":"Updated diagnostic criteria and classification of mast cell disorders: A consensus proposal","volume":"5","author":"Valent","year":"2021","journal-title":"Hemasphere"},{"key":"10.1016\/j.pharmthera.2025.108892_bb1140","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","article-title":"Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts","volume":"129","author":"Valent","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2025.108892_bb1145","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1111\/all.12227","article-title":"Anaphylactic responses to histamine in mice utilize both histamine receptors 1 and 2","volume":"68","author":"Wechsler","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.pharmthera.2025.108892_bb1150","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20010019","article-title":"Mast cell-specific expression of human Siglec-8 in conditional knock-in mice","volume":"20","author":"Wei","year":"2018","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2025.108892_bb1155","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/nri3690","article-title":"Mast cell secretory granules: Armed for battle","volume":"14","author":"Wernersson","year":"2014","journal-title":"Nature Reviews. Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb1160","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.4049\/jimmunol.139.8.2605","article-title":"125I-fibrin deposition in IgE-dependent immediate hypersensitivity reactions in mouse skin. Demonstration of the role of mast cells using genetically mast cell-deficient mice locally reconstituted with cultured mast cells","volume":"139","author":"Wershil","year":"1987","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb1165","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0091-6749(05)80223-4","article-title":"The role of histamine in allergic diseases","volume":"86","author":"White","year":"1990","journal-title":"The Journal of Allergy and Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb1170","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.jaci.2024.07.002","article-title":"Inhibition of mast cell degranulation by novel small molecule MRGPRX2 antagonists","volume":"154","author":"Wollam","year":"2024","journal-title":"The Journal of Allergy and Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb1175","doi-asserted-by":"crossref","first-page":"1406438","DOI":"10.3389\/fimmu.2024.1406438","article-title":"MRGPRX2 antagonist GE1111 attenuated DNFB-induced atopic dermatitis in mice by reducing inflammatory cytokines and restoring skin integrity","volume":"15","author":"Wong","year":"2024","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb1180","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJMoa2312382","article-title":"Omalizumab for the treatment of multiple food allergies","volume":"390","author":"Wood","year":"2024","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2025.108892_bb1185","doi-asserted-by":"crossref","first-page":"11581","DOI":"10.1038\/srep11581","article-title":"Structural and physical basis for anti-IgE therapy","volume":"5","author":"Wright","year":"2015","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2025.108892_bb1190","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1084\/jem.185.4.663","article-title":"IgE enhances mouse mast cell Fc(epsilon)RI expression in vitro and in vivo: Evidence for a novel amplification mechanism in IgE-dependent reactions","volume":"185","author":"Yamaguchi","year":"1997","journal-title":"The Journal of Experimental Medicine"},{"issue":"499\u2013505","key":"10.1016\/j.pharmthera.2025.108892_bb1195","article-title":"Inhibition of FcepsilonRI-dependent mediator release and calcium flux from human mast cells by sialic acid-binding immunoglobulin-like lectin 8 engagement","volume":"121","author":"Yokoi","year":"2008","journal-title":"The Journal of Allergy and Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb1200","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1398-9995.2006.01133.x","article-title":"Alteration and acquisition of Siglecs during in vitro maturation of CD34+ progenitors into human mast cells","volume":"61","author":"Yokoi","year":"2006","journal-title":"Allergy"},{"key":"10.1016\/j.pharmthera.2025.108892_bb1205","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126219","article-title":"Siglec-8 antibody reduces eosinophils and mast cells in a transgenic mouse model of eosinophilic gastroenteritis","volume":"4","author":"Youngblood","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.pharmthera.2025.108892_bb1210","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000501637","article-title":"AK002, a humanized sialic acid-binding immunoglobulin-like Lectin-8 antibody that induces antibody-dependent cell-mediated cytotoxicity against human eosinophils and inhibits mast cell-mediated anaphylaxis in mice","volume":"180","author":"Youngblood","year":"2019","journal-title":"International Archives of Allergy and Immunology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb1215","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1172\/JCI25702","article-title":"Mast cells can promote the development of multiple features of chronic asthma in mice","volume":"116","author":"Yu","year":"2006","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2025.108892_bb1220","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.cell.2007.05.055","article-title":"Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor","volume":"130","author":"Yuzawa","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2025.108892_bb1225","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1159\/000479878","article-title":"Drug-induced pseudoallergy: A review of the causes and mechanisms","volume":"101","author":"Zhang","year":"2018","journal-title":"Pharmacology"},{"key":"10.1016\/j.pharmthera.2025.108892_bb1230","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108256","article-title":"Recent advances in metabolism and toxicity of tyrosine kinase inhibitors","volume":"237","author":"Zhao","year":"2022","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2025.108892_bb1235","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1111\/all.13397","article-title":"The EAACI\/GA(2)LEN\/EDF\/WAO guideline for the definition, classification, diagnosis and management of urticaria","volume":"73","author":"Zuberbier","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.pharmthera.2025.108892_bb1240","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0140-6736(24)00852-3","article-title":"Chronic urticaria: Unmet needs, emerging drugs, and new perspectives on personalised treatment","volume":"404","author":"Zuberbier","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2025.108892_bb01242","doi-asserted-by":"crossref","DOI":"10.4084\/MJHID.2022.040","article-title":"Treatment of Indolent and Advanced Systemic Mastocytosis","volume":"14","author":"Buonomo","year":"2022","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.pharmthera.2025.108892_bb01243","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood-2014-12-614743","article-title":"Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis","volume":"126","author":"Barete","year":"2015","journal-title":"Blood"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725825001044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725825001044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T04:59:40Z","timestamp":1776833980000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725825001044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":258,"alternative-id":["S0163725825001044"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2025.108892","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current and future therapeutics targeting mast cells in disease","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2025.108892","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108892"}}